The FSE Group acts as manager for CPCA Business Growth Finance Limited.
The investment forms part of a £1m round backed by The FSE Group and Waterspring Ventures.
"This funding is allowing us to invest in key activities to accelerate our growth trajectory and solidify our position in the market. Planned developments mean we can continue to provide customers with unparalleled insights at exceptional value. We are excited to partner with The FSE Group and South West Investment Fund as we continue to expand our capabilities and enhance our platform."
The seed round was led by The FSE Group via the South West Investment Fund, with participation from Fuel Ventures.
"Building a healthy workplace culture is a collective responsibility; employees need to feel equipped, safe and protected, with Employee Relations and Compliance empowered and accountable. Our platform supports organisations to act fairly, kindly and responsibly, reaping the benefits of the Safe Workplace they create. We are delighted to receive this South West Investment Fund funding, which will enable us to further develop our product and expand our team."
The seafood restaurant group has raised capital, including a £1.3m investment from The FSE Group, to open new sites and expand its retail offerings.
"This investment is a testament to the strength and potential of Rockfish. We are excited to embark on this next chapter of growth, driven by our passion for seafood and our commitment to sustainability and excellence. We are grateful for the support from the South West Investment Fund and The FSE Group and look forward to bringing our unique seafood experience to even more people."
Soulmates Ventures and Deeptech Seed Fund co-led the seed round, which includes £500k from Innovate UK.
"I couldn't be more excited and proud about this next stage in our growth. It is a landmark opportunity, a once in a lifetime moment, to build a transformative product."
The financing round will help the medical technology company advance its epilepsy diagnosis software towards US and Middle Eastern markets.
"We are delighted to have invested in Neuronostics, whose software as a medical device could revolutionise how neurological conditions are diagnosed and treated."
